Screener
Relay Therapeutics, Inc. RLAY Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income: | ||||
| Interest income | 7,115 | 7,105 | 12,467 | 14,918 |
| Other income (expense) | 2 | (633) | (51) | (641) |
| Total other income, net | 7,117 | 6,472 | 12,416 | 14,277 |
| Net loss | $(83,707) | $(70,375) | $(156,998) | $(147,440) |
| Net loss per share, basic and diluted | $(0.41) | $(0.41) | $(0.82) | $(0.87) |
| Weighted average shares of common stock, basic and diluted | 202,849,466 | 171,264,622 | 191,412,839 | 170,254,500 |
| Other comprehensive (loss) income: |
Item 1. Financial Statements.
FAQ
- What is Relay Therapeutics, Inc.'s other income, net (note 6)?
- Relay Therapeutics, Inc. (RLAY) reported other income, net (note 6) of $7.12M in Q2 2026.
- How has Relay Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
- Relay Therapeutics, Inc.'s other income, net (note 6) increased by 10.0% year-over-year, from $6.47M to $7.12M.
- What is the long-term trend for Relay Therapeutics, Inc.'s other income, net (note 6)?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s other income, net (note 6) has grown at a 137.4% compound annual growth rate (CAGR), from $826K to $26.26M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Relay Therapeutics, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude